drugset / Trial / NCT01584284

Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer

NCT01584284

Phase 1 Completed 19 enrolled Genelux GmbH
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and tolerability of GL-ONC1 administered intravenously in combination with radiation therapy and cisplatin (CDDP)in patients with locoregionally advanced head and neck cancer.

Timeline

Start
2012-04
Primary completion
2015-06
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Olvimulogene nanivacirepvec Other / unclassified Intravenous

Indications